nach oben

Erschienen in:

09.08.2020 | Epidemiology

Frequency and spectrum of founder and non-founder BRCA1 and BRCA2 mutations in a large series of Russian breast cancer and ovarian cancer patients

verfasst von: Anna P. Sokolenko, Tatiana N. Sokolova, Valeria I. Ni, Elena V. Preobrazhenskaya, Aglaya G. Iyevleva, Svetlana N. Aleksakhina, Alexandr A. Romanko, Alexandr A. Bessonov, Tatiana V. Gorodnova, Elena I. Anisimova, Elena L. Savonevich, Ilya V. Bizin, Ilya A. Stepanov, Petr V. Krivorotko, Igor V. Berlev, Alexey M. Belyaev, Alexandr V. Togo, Evgeny N. Imyanitov

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

The spectrum of BRCA1 and BRCA2 mutations in Slavic countries is characterized by a high prevalence of founder alleles.

Methods

We analyzed a large data set of Russian breast cancer (BC) and ovarian cancer (OC) patients, who were subjected to founder mutation tests or full-length BRCA1 and BRCA2 analysis.

Results

The most commonly applied test, which included four founder mutations (BRCA1: 5382insC, 4153delA, 185delAG; BRCA2: 6174delT), identified BRCA1 or BRCA2 heterozygosity in 399/8533 (4.7%) consecutive BC patients, 230/2317 (9.9%) OC patients, and 30/118 (25.4%) women with a combination of BC and OC. The addition of another four recurrent BRCA1 mutations to the test (BRCA1 C61G, 2080delA, 3819del5, 3875del4) resulted in evident increase in the number of identified mutation carriers (BC: 16/993 (1.6%); OC: 34/1289 (2.6%); BC + OC: 2/39 (5.1%)). Full-length sequencing of the entire BRCA1 and BRCA2 coding region was applied to 785 women, very most of whom demonstrated clinical signs of BRCA-driven disease, but turned out negative for all described above founder alleles. This analysis revealed additional BRCA1 or BRCA2 mutation carriers in 54/282 (19.1%) BC, 50/472 (10.6%) OC, and 13/31 (42%) BC + OC patients. The analysis of frequencies of founder and “rare” BRCA1 and BRCA2 pathogenic alleles across various clinical subgroups (BC vs. OC vs. BC + OC; family history positive vs. negative; young vs. late-onset; none vs. single vs. multiple clinical indicators of BRCA1- or BRCA2-associated disease) revealed that comprehensive BRCA1 and BRCA2 analysis increased more than twice the number of identified mutation carriers in all categories of the examined women.

Conclusion

Full-length BRCA1 and BRCA2 sequencing is strongly advised to Slavic subjects, who have medical indications for BRCA1 and BRCA2 testing but are negative for recurrent BRCA1 and BRCA2 mutations.

Nur mit Berechtigung zugänglich

Kast K, Rhiem K, Wappenschmidt B, Hahnen E, Hauke J, Bluemcke B, Zarghooni V, Herold N, Ditsch N, Kiechle M, Braun M, Fischer C, Dikow N, Schott S, Rahner N, Niederacher D, Fehm T, Gehrig A, Mueller-Reible C, Arnold N, Maass N, Borck G, de Gregorio N, Scholz C, Auber B, Varon-Manteeva R, Speiser D, Horvath J, Lichey N, Wimberger P, Stark S, Faust U, Weber BH, Emons G, Zachariae S, Meindl A, Schmutzler RK, Engel C, German Consortium for Hereditary Breast, and Ovarian Cancer (GCHBOC) (2016) Prevalence of BRCA1/2 germline mutations in 21401 families with breast and ovarian cancer. J Med Genet 53:465–471. https://doi.org/10.1136/jmedgenet-2015-103672CrossRef

Neff RT, Senter L, Salani R (2017) BRCA mutation in ovarian cancer: testing, implications and treatment considerations. Ther Adv Med Oncol 9:519–531. https://doi.org/10.1177/1758834017714993CrossRef

Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, Garber JE, Neuhausen SL, Matloff E, Eeles R, Pichert G, Van t'veer L, Tung N, Weitzel JN, Couch FJ, Rubinstein WS, Ganz PA, Daly MB, Olopade OI, Tomlinson G, Schildkraut J, Blum JL, Rebbeck TR (2010) Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 304:967–975. https://doi.org/10.1001/jama.2010.1237CrossRef

Ludwig KK, Neuner J, Butler A, Geurts JL, Kong AL (2016) Risk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review. Am J Surg 212:660–669. https://doi.org/10.1016/j.amjsurg.2016.06.010CrossRef

Paluch-Shimon S, Cardoso F, Sessa C, Balmana J, Cardoso MJ, Gilbert F, Senkus E, Guidelines Committee ESMO (2016) Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening. Ann Oncol 27(suppl 5):v103–v110. https://doi.org/10.1093/annonc/mdw327CrossRef

Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434:913–917. https://doi.org/10.1038/nature03443CrossRef

Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith GC, Ashworth A (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434:917–921. https://doi.org/10.1038/nature03445CrossRef

Byrski T, Huzarski T, Dent R, Marczyk E, Jasiowka M, Gronwald J, Jakubowicz J, Cybulski C, Wisniowski R, Godlewski D, Lubinski J, Narod SA (2014) Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat 147:401–405. https://doi.org/10.1007/s10549-014-3100-xCrossRef

Iyevleva AG, Imyanitov EN (2016) Cytotoxic and targeted therapy for hereditary cancers. Hered Cancer Clin Pract 14(1):17. https://doi.org/10.1186/s13053-016-0057-2CrossRef

10.

Hartge P, Struewing JP, Wacholder S, Brody LC, Tucker MA (1999) The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. Am J Hum Genet 64:963–970. https://doi.org/10.1086/302320CrossRef

11.

Tulinius H, Olafsdottir GH, Sigvaldason H, Arason A, Barkardottir RB, Egilsson V, Ogmundsdottir HM, Tryggvadottir L, Gudlaugsdottir S, Eyfjord JE (2002) The effect of a single BRCA2 mutation on cancer in Iceland. J Med Genet 39:457–462. https://doi.org/10.1136/jmg.39.7.457CrossRef

12.

Górski B, Jakubowska A, Huzarski T, Byrski T, Gronwald J, Grzybowska E, Mackiewicz A, Stawicka M, Bebenek M, Sorokin D, Fiszer-Maliszewska Ł, Haus O, Janiszewska H, Niepsuj S, Góźdź S, Zaremba L, Posmyk M, Płuzańska M, Kilar E, Czudowska D, Waśko B, Miturski R, Kowalczyk JR, Urbański K, Szwiec M, Koc J, Debniak B, Rozmiarek A, Debniak T, Cybulski C, Kowalska E, Tołoczko-Grabarek A, Zajaczek S, Menkiszak J, Medrek K, Masojć B, Mierzejewski M, Narod SA, Lubiński J (2004) A high proportion of founder BRCA1 mutations in Polish breast cancer families. Int J Cancer 110:683–686. https://doi.org/10.1002/ijc.20162CrossRef

13.

Savanevich A, Oszurek O, Lubiński J, Cybulski C, Dębniak T, Narod SA, Gronwald J (2014) BRCA1 founder mutations compared to ovarian cancer in Belarus. Fam Cancer 13:445–447. https://doi.org/10.1007/s10689-014-9721-8CrossRef

14.

Sokolenko AP, Mitiushkina NV, Buslov KG, Bit-Sava EM, Iyevleva AG, Chekmariova EV, Kuligina ESh, Ulibina YM, Rozanov ME, Suspitsin EN, Matsko DE, Chagunava OL, Trofimov DY, Devilee P, Cornelisse C, Togo AV, Semiglazov VF, Imyanitov EN (2006) High frequency of BRCA1 5382insC mutation in Russian breast cancer patients. Eur J Cancer 42:1380–1384. https://doi.org/10.1016/j.ejca.2006.01.050CrossRef

15.

Sokolenko AP, Rozanov ME, Mitiushkina NV, Sherina NY, Iyevleva AG, Chekmariova EV, Buslov KG, Shilov ES, Togo AV, Bit-Sava EM, Voskresenskiy DA, Chagunava OL, Devilee P, Cornelisse C, Semiglazov VF, Imyanitov EN (2007) Founder mutations in early-onset, familial and bilateral breast cancer patients from Russia. Fam Cancer 6:281–286. https://doi.org/10.1007/s10689-007-9120-5CrossRef

16.

Iyevleva AG, Suspitsin EN, Kroeze K, Gorodnova TV, Sokolenko AP, Buslov KG, Voskresenskiy DA, Togo AV, Kovalenko SP, Nv S, Devilee P, Imyanitov EN (2010) Non-founder BRCA1 mutations in Russian breast cancer patients. Cancer Lett 298:258–263. https://doi.org/10.1016/j.canlet.2010.07.013CrossRef

17.

Golden Helix GenomeBrowse ® visualization tool (Version 2.x) [Software]. Bozeman, MT: Golden Helix, Inc. https://www.goldenhelix.com.

18.

Rebbeck TR, Mitra N, Wan F, Sinilnikova OM, Healey S, McGuffog L, Mazoyer S, Chenevix-Trench G, Easton DF, Antoniou AC, Nathanson KL, and the CIMBA Consortium (2015) Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA 313:1347–1361. https://doi.org/10.1001/jama.2014.5985CrossRef

19.

Manahan ER, Kuerer HM, Sebastian M, Hughes KS, Boughey JC, Euhus DM, Boolbol SK, Taylor WA (2019) Consensus Guidelines on Genetic` Testing for Hereditary Breast Cancer from the American Society of Breast Surgeons. Ann Surg Oncol 26:3025–3031. https://doi.org/10.1245/s10434-019-07549-8CrossRef

20.

Kluska A, Balabas A, Paziewska A, Kulecka M, Nowakowska D, Mikula M, Ostrowski J (2015) New recurrent BRCA1/2 mutations in Polish patients with familial breast/ovarian cancer detected by next generation sequencing. BMC Med Genomics 8:19. https://doi.org/10.1186/s12920-015-0092-2CrossRef

21.

Brozek I, Cybulska C, Ratajska M, Piatkowska M, Kluska A, Balabas A, Dabrowska M, Nowakowska D, Niwinska A, Pamula-Pilat J, Tecza K, Pekala W, Rembowska J, Nowicka K, Mosor M, Januszkiewicz-Lewandowska D, Rachtan J, Grzybowska E, Nowak J, Steffen J, Limon J (2011) Prevalence of the most frequent BRCA1 mutations in Polish population. J Appl Genet 52:325–330. https://doi.org/10.1007/s13353-011-0040-6CrossRef

22.

Kowalik A, Siołek M, Kopczyński J, Krawiec K, Kalisz J, Zięba S, Kozak-Klonowska B, Wypiórkiewicz E, Furmańczyk J, Nowak-Ozimek E, Chłopek M, Macek P, Smok-Kalwat J, Góźdź S (2018) BRCA1 founder mutations and beyond in the Polish population: A single-institution BRCA1/2 next-generation sequencing study. PLoS ONE 13:e0201086. https://doi.org/10.1371/journal.pone.0201086CrossRef

23.

Cybulski C, Kluźniak W, Huzarski T, Wokołorczyk D, Kashyap A, Rusak B, Stempa K, Gronwald J, Szymiczek A, Bagherzadeh M, Jakubowska A, Dębniak T, Lener M, Rudnicka H, Szwiec M, Jarkiewicz-Tretyn J, Stawicka M, Domagała P, Narod SA, Lubiński J, Akbari MR, Polish Hereditary Breast Cancer Consortium (2019) The spectrum of mutations predisposing to familial breast cancer in Poland. Int J Cancer 145:3311–3320. https://doi.org/10.1002/ijc.32492CrossRef

24.

Gorodnova T, Sokolenko A, Ni V, Ivantsov A, Kotiv K, Petrik S, Amelina I, Berlev I, Imyanitov E (2019) BRCA1-associated and sporadic ovarian carcinomas: outcomes of primary cytoreductive surgery or neoadjuvant chemotherapy. Int J Gynecol Cancer 29:779–786. https://doi.org/10.1136/ijgc-2018-000175CrossRef

25.

Gorodnova TV, Kotiv KB, Ivantsov AO, Mikheyeva ON, Mikhailiuk GI, Lisyanskaya AS, Mikaya NA, Guseynov KD, Bondarev NE, Matveyeva NS, Nekrasova EA, Sidoruk AA, Roman LD, Manikhas GM, Belyaev AM, Sokolenko AP, Berlev IV, Imyanitov EN (2018) Efficacy of Neoadjuvant Therapy With Cisplatin Plus Mitomycin C in BRCA1-Mutated Ovarian Cancer. Int J Gynecol Cancer 28:1498–1506. https://doi.org/10.1097/IGC.0000000000001352CrossRef

26.

Preobrazhenskaya EV, Bizin IV, Kuligina ES, Shleykina AY, Suspitsin EN, Zaytseva OA, Anisimova EI, Laptiev SA, Gorodnova TV, Belyaev AM, Imyanitov EN, Sokolenko AP (2017) Detection of BRCA1 gross rearrangements by droplet digital PCR. Breast Cancer Res Treat 165:765–770. https://doi.org/10.1007/s10549-017-4357-7CrossRef

27.

Mancini-DiNardo D, Judkins T, Kidd J, Bernhisel R, Daniels C, Brown K, Meek K, Craft J, Holladay J, Morris B, Roa BB (2019) Detection of large rearrangements in a hereditary pan-cancer panel using next-generation sequencing. BMC Med Genomics 12(1):138. https://doi.org/10.1186/s12920-019-0587-3CrossRef

28.

Moiseyenko VM, Chubenko VA, Moiseyenko FV, Zagorskaya LA, Zaytseva YA, Gesha NE, Zykov EN, Ni VI, Preobrazhenskaya EV, Sokolenko AP, Imyanitov EN (2018) “Lazarus Response” to Olaparib in a Virtually Chemonaive Breast Cancer Patient Carrying Gross BRCA2 Gene Deletion. Cureus 10(2):e2150. https://doi.org/10.7759/cureus.2150CrossRef

29.

Sokolenko AP, Imyanitov EN (2018) Molecular Diagnostics in Clinical Oncology. Front Mol Biosci 5:76. https://doi.org/10.3389/fmolb.2018.00076CrossRef

Titel: Frequency and spectrum of founder and non-founder BRCA1 and BRCA2 mutations in a large series of Russian breast cancer and ovarian cancer patients
verfasst von: Anna P. Sokolenko
Tatiana N. Sokolova
Valeria I. Ni
Elena V. Preobrazhenskaya
Aglaya G. Iyevleva
Svetlana N. Aleksakhina
Alexandr A. Romanko
Alexandr A. Bessonov
Tatiana V. Gorodnova
Elena I. Anisimova
Elena L. Savonevich
Ilya V. Bizin
Ilya A. Stepanov
Petr V. Krivorotko
Igor V. Berlev
Alexey M. Belyaev
Alexandr V. Togo
Evgeny N. Imyanitov
Publikationsdatum: 09.08.2020
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 1/2020
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-020-05827-8

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Frequency and spectrum of founder and non-founder BRCA1 and BRCA2 mutations in a large series of Russian breast cancer and ovarian cancer patients